Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Information by Drug Class

Information by Drug Class

                        Prescription Stimulant Medications


                        Human Immunodeficiency Virus (HIV) Home
          Drugs
          Drug Safety and Availability
          Information by Drug Class
          Opioid MedicationsInformation by Drug Class Opioid Medications
  
  	
    Share
    Post
    Linkedin

    Email
    PrintPrescription opioids are powerful pain-reducing medications that include oxycodone, hydrocodone, and morphine, among others, and have both benefits as well as potentially serious risks. However, too many Americans have been impacted by the serious harms associated with these medications, and despite ongoing efforts, the scope of the opioid crisis continues to grow.

One of the highest priorities of the FDA is advancing efforts to address the crisis of misuse and abuse of opioid drugs harming families. Opioids are claiming lives at a staggering rate, and overdoses from prescription opioids are reducing life expectancy in the United States.

At FDA, we’re working across the full scope of our regulatory obligations to impact this crisis. Our approach to reducing the misuse and abuse of opioids is outlined in FDA’s 2018 Strategic Policy Roadmap, which addresses various facets of this complex issue, as there are no simple answers to reverse this epidemic.

Decrease Exposure & Prevent New Addiction

Reducing the number of Americans who are addicted to opioids and cutting the rate of new addiction is one of the FDA’s highest priorities. This may be achieved by ensuring that only appropriately indicated patients are prescribed opioids and that the prescriptions are for durations and doses that properly match the clinical reason for which the drug is being prescribed in the first place.

SUPPORT Act Section 3002: Report on Evidence-Based Opioid Analgesic Prescribing Guidelines (PDF - 225 KB)
	SUPPORT Act Section 7024: Report to Congress on Opioid Prescribing Limits (PDF - 871 KB)
	Opioid Policy Steering Committee (OPSC)
	Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
	FDA Opioid Systems Modeling Effort
	Disposal of Unused Medicines: What You Should KnowSupport Treatment of Those with Opioid Use Disorder

Given the scale of the opioid crisis, with millions of Americans already affected, prevention is not enough. We must do everything possible to address the human toll caused by opioid use disorder and help those suffering from addiction by expanding access to lifesaving treatment.

Medication-Assisted Treatment (MAT)
	Naloxone
	FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use DisorderFoster Development of Novel Pain Treatment Therapies

As we continue to confront opioid abuse and addiction, we must also take steps to help those with acute and chronic pain who need access to medicines, including opioids, get improved treatment alternatives. Transitioning from the current market, dominated by conventional opioids, to one in which most opioids have abuse-deterrent properties, holds significant promise for a meaningful public health benefit. While these innovative formulations are designed to make it harder for people to manipulate the opioid drug so they can’t be abused, it’s important that prescribers and patients understand that these drugs are not “abuse-proof,” and they do not prevent addiction, overdose, or death.

SUPPORT Act Section 6012: Report on Abuse-Deterrent Opioid Formulations and Access Barriers Under Medicare (PDF - 698 KB)
	Abuse-Deterrent Formulations
	Patient-Focused Drug Development for Chronic PainImprove Enforcement & Assess Benefit/Risk

The FDA plays an enforcement role when it comes to the illicit market for diverted opioids and illegal drugs. One of those roles is collaborating with Customs and Border Protection on interdiction work on drugs being shipped through the mail. The agency has received new funding for processing drugs and other articles imported or offered for import through International Mail Facilities. A lot of the illicit drugs brought into the U.S., including products laced with lethal doses of fentanyl, are being purchased online and shipped in the mail. Although the sale of prescription opioids without a valid prescription is illegal, the FDA continues to see these products in the packages we inspect.

FDA takes action against websites marketing unapproved opioids
	Online Opioid SummitIn addition, part of our ongoing work is ensuring that drug approval and removal decisions are made within a benefit/risk framework that evaluates not only the outcomes of opioids when used a prescribed, but also the public health effects of inappropriate use of these drugs. We are continually re-evaluating the safety of approved opioid products based on both post-market data the FDA has required from sponsors and additional sources of information as part of our safety surveillance.

Opioid Analgesic Drugs: Considerations for Benefit/Risk Assessment Framwork (draft guidance)
	Standards for Future Opioid Analgesic Approach and Incentives for New Therapeutics to Treat Pain and Addiction (public meeting)
	Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
	Oxymorphone (marketed as Opana ER) InformationTimeline

The FDA has compiled a timeline to provide chronological information about agency activities and significant events related to opioids. Included on this page is a summary timeline of key events, followed by tabbed years that provide selected additional actions and more detail about the items listed in the summary.

Related Resources

Safe Opioid Disposal - Remove the Risk Outreach Toolkit
	Safety Measures for Immediate Release (IR) Opioids
	Safety Measures for Extended-release and Long-acting (ER/LA) Opioids
	Safety Measures for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines
	Search and Rescue: Connecting prescribers to resources to help prevent drug misuse and abuse in their practicesResources For You

HHS Opioids
	CDC: Injury Prevention and Control: Prescription Drug Overdose
	Substance Abuse and Mental Health Services Administration: Opioids
	National Institute on Drug Abuse: Opioids

                                                                                  Content current as of:
      03/29/2021Information by Drug Class

          
                        Prescription Stimulant Medications


                        Human Immunodeficiency Virus (HIV)
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop